loading

R&D

Research

  • Neuronanta-R

    2023.12.19

    Biological markers of Mesenchymal Stromal Cells as Predictors of response to Autologous Stem Cell Transplantation in Patients with Amyotrophic Lateral Sclerosis; an investigator-initiaited Trial and in Vivo Study
    Biological markers of Mesenchymal Stromal Cells as Predictors of response to Autologous Stem Cell Transplantation in Patients with Amyotrophic Lateral Sclerosis; an investigator-initiaited Trial and in Vivo Study

    • Publication information

      Stem Cells Translational Medicine. 2015 Jun;4(6):590-7.

    • Author

      HYUN YOUNG KIM,a HEEJAUNG KIM,b KI-WOOK OH,a SEONG-IL OH,a SEONG-HO KOH,a WONKI BAIK,a MIN YOUNG NOH,a KYUNG SUK KIM,c SEUNG HYUN KIM a

  • Neuronanta-R

    2023.07.14

    Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cell treatment in ALS
    Neuronata-R® (lenzumestrocel) is an autologous bone marrowderived mesenchymal stem cell (BM-MSC) product, which was conditionally approved by the Korean Ministry of Food and Drug Safety (KMFDS, Republic of Korea) in 2013 for the treatment of amyotrophic lateral sclerosis (ALS).
    In thepresent study, we aimed to investigate the long-term survival benefits of treatment with intrathecal lenzumestrocel.

    • Publication information

      12 April 2023 ; Frontiers in Aging Neuroscience

    • Author

      Jae-Yong Nam 1, Sehwan Chun 1,2, Tae Yong Lee 1,3, Yunjeong Seo 1, Kwijoo Kim 1, Jinseok Park 4, Wonjae Sung 4, Ki-Wook Oh 4, Sanggon Lee 4,5, Jin-Sung Park 6, Juyeon Oh 7, Kyung Cheon Chung 8, Hyonggin An 9, Hyeon Sik Chu 10, Bugyeong Son 10 and Seu

  • Neuronanta-R

    2023.07.14

    Efficacy and safety of Lenzumestrocel in patients with amyotrophic lateral sclerosis
    A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymalstem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in patients with ALS but did not demonstrate long-term efficacy. This phase III clinical trial (ALSUMMIT) protocol was developed to evaluate the long-term efficacy and safety of the combined protocol of single-cycle intrathecal therapy and three additional booster injections of BM-MSC (Lenzumestrocel) treatment in patients with ALS.

    • Publication information

      Efficacy and safety of Lenzumestrocel (Neuronata‑R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double‑blind, parallel‑group, sham procedure‑controlled, phase III trial

    • Author

      Jae‑Yong Nam1†, Tae Yong Lee1,6†, Kwijoo Kim1, Sehwan Chun1, Min Sung Kim1,6, Jin‑Hong Shin2, Jung‑Joon Sung3, Byoung Joon Kim4, Byung‑Jo Kim5, Ki‑Wook Oh7, Kyung Suk Kim1* and Seung Hyun Kim7*

  • Neuronanta-R

    2023.07.14

    Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
    The result paper of the Neuronata-R Phase 2 clinical trial.

    • Publication information

      ANN NEUROL 2018;84:361–373

    • Author

      Ki-Wook Oh, MD, PhD,1,2 Min-Young Noh, PhD,1,2 Min-Soo Kwon, MD, PhD,3 Hyun Young Kim, MD, PhD,1,2 Seong-il Oh, MD, PhD,4 Jinseok Park, MD,1,2 Hee-Jin Kim, MD, PhD,1,2 Chang-Seok Ki, MD, PhD,5 and Seung Hyun Kim, MD, PhD1,2